- Home
- NFGC vs IMMP Comparison
NFGC vs IMMP Comparison
Compare NFGC & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NFGC
- IMMP
- Stock Information
- Founded
- NFGC 2016
- IMMP 1987
- Country
- NFGC Canada
- IMMP Australia
- Employees
- NFGC N/A
- IMMP N/A
- Industry
- NFGC Precious Metals
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- NFGC Basic Materials
- IMMP Health Care
- Exchange
- NFGC Nasdaq
- IMMP Nasdaq
- Market Cap
- NFGC 261.0M
- IMMP 251.8M
- IPO Year
- NFGC N/A
- IMMP N/A
- Fundamental
- Price
- NFGC $1.51
- IMMP $1.60
- Analyst Decision
- NFGC Strong Buy
- IMMP Buy
- Analyst Count
- NFGC 1
- IMMP 1
- Target Price
- NFGC $5.00
- IMMP $7.00
- AVG Volume (30 Days)
- NFGC 2.1M
- IMMP 101.9K
- Earning Date
- NFGC 08-08-2025
- IMMP 02-27-2025
- Dividend Yield
- NFGC N/A
- IMMP N/A
- EPS Growth
- NFGC N/A
- IMMP N/A
- EPS
- NFGC N/A
- IMMP N/A
- Revenue
- NFGC N/A
- IMMP $3,019,249.00
- Revenue This Year
- NFGC N/A
- IMMP $50.37
- Revenue Next Year
- NFGC N/A
- IMMP N/A
- P/E Ratio
- NFGC N/A
- IMMP N/A
- Revenue Growth
- NFGC N/A
- IMMP 24.11
- 52 Week Low
- NFGC $0.93
- IMMP $1.32
- 52 Week High
- NFGC $3.65
- IMMP $2.80
- Technical
- Relative Strength Index (RSI)
- NFGC 57.02
- IMMP 34.41
- Support Level
- NFGC $1.42
- IMMP $1.81
- Resistance Level
- NFGC $1.56
- IMMP $1.92
- Average True Range (ATR)
- NFGC 0.08
- IMMP 0.08
- MACD
- NFGC -0.01
- IMMP -0.03
- Stochastic Oscillator
- NFGC 28.57
- IMMP 0.00
About NFGC New Found Gold Corp
New Found Gold Corp is a mineral exploration company engaged in the acquisition, exploration and evaluation of resource properties with a focus on gold properties located in the Provinces of Newfoundland and Labrador and Ontario, Canada. The Company's exploration is focused on discovering and delineating gold resources. The Company has one material property: the Queensway Project located in Newfoundland, Canada (the Queensway Project).
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.